Make a ppt of 25 slides on topic endometriosis recurrence it's prevention and management from standard text book like barek and Novak williams text book of Gynaecology and latest standard international journals and article
"endometriosis"[MeSH Terms] AND "recurrence"[MeSH Terms] AND "prevention"
"endometriosis"[MeSH Terms] AND "secondary prevention" AND "medical therapy"
"endometriosis"[MeSH Terms] AND "recurrence" AND "hormonal treatment"
"endometriosis"[MeSH Terms] AND "GnRH agonist" AND "recurrence prevention"
"endometriosis"[MeSH Terms] AND "surgical treatment" AND "recurrence"
"endometriosis"[MeSH Terms] AND "dienogest" AND "recurrence"
"endometriosis"[MeSH Terms] AND "elagolix" OR "relugolix" OR "linzagolix"
Endometriosis Recurrence Prevention Management
Presentation · PPTX
What's Inside — 25 Slides
| Slide | Content |
|---|---|
| 1 | Title slide — Endometriosis Recurrence: Prevention and Management |
| 2 | Learning Objectives — 9 objectives covering all major domains |
| 3 | Endometriosis Overview — definition, prevalence, sites, ASRM staging, recurrence concept |
| 4 | Key Statistics infographic — 27% at 24 months, 40–80% at 5 years, 10% prevalence |
| 5 | Section Divider — Pathophysiology of Recurrence |
| 6 | Pathophysiology — retrograde menstruation, residual disease, aromatase, immune dysregulation, epigenetics |
| 7 | Risk Factors (two-column) — disease/patient factors vs. surgical/hormonal factors |
| 8 | ASRM Staging Table — Stages I–IV with points and 5-year recurrence risk |
| 9 | Section Divider — Prevention of Recurrence |
| 10 | Rationale for Postoperative Suppression — ESHRE 2022 recommendations |
| 11 | COCP — mechanism, efficacy, PRE-EMPT RCT 2024 data |
| 12 | Progestin Therapy — dienogest meta-analysis 2023 (n=1,668), DMPA, LNG-IUS, NETA |
| 13 | GnRH Agonists — agents, add-back, bone density, duration limits |
| 14 | New Oral GnRH Antagonists — Relugolix SPIRIT 1&2 (Lancet 2022), Elagolix, Linzagolix |
| 15 | LNG-IUS & Non-Hormonal Options — aromatase inhibitors, NAC, NSAIDs, physiotherapy |
| 16 | Section Divider — Surgical Management of Recurrence |
| 17 | Surgical Principles — indications, laparoscopy, excision vs ablation, MDT |
| 18 | Cystectomy vs. Ablation Evidence Table — 6 outcomes with Odds Ratios from Cochrane |
| 19 | Recurrence Rates infographic — 4%/17%/27% at 3/12/24 months (meta-analysis 2024) |
| 20 | DIE Surgery — bowel, ureter, bladder, retroperitoneal dissection, nerve-sparing |
| 21 | Section Divider — Long-Term Management |
| 22 | Fertility-Preserving Management (two-column) — surgical vs. ART pathways, AMH monitoring |
| 23 | Surveillance & Follow-Up — imaging, CA-125, EHP-30, DEXA, psychology |
| 24 | Clinical Algorithm — 5-step decision pathway (fertility status, medical/surgical, post-treatment) |
| 25 | Summary — 8 Key Take-Home Messages on dark background with gold numbered boxes |